Viberzi (eluxadoline) is a prescription drug used to treat irritable bowel syndrome with diarrhea. Viberzi’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

Allergan is working to grow its market share for IBS-D therapy Viberzi. And to that end, it’s rolling out a new tool that it hopes will help grow the market. Earlier this week, the company launched ...

Please provide your email address to receive an email when new articles are posted on . Viberzi safely and effectively reduced symptoms of irritable bowel syndrome with diarrhea, according to the ...

Some of Allergan’s key products are coming up against serious competition--meaning it’ll be up to the Dublin drugmaker’s new launches to keep the engine going strong. The way one analyst sees it, that ...

The FDA has issued a warning for Viberzi that patients who do not have a gallbladder have an increased risk of developing serious pancreatitis. The FDA has issued a warning for Viberzi, which is used ...

Eluxadoline (Viberzi, Allergan), a drug used to treat irritable bowel syndrome (IBS) with diarrhea, should not be used in patients who do not have a gallbladder, the US Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with diarrhea-predominant irritable bowel syndrome who previously had an inadequate ...

Recently, with the FDA approval of Allergan’s Viberzi and Valeant Pharmaceuticals’ Xifaxan, as well as the low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet, ...

Actavis plcACT announced that the FDA approved Viberzi (eluxadoline) as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D). Approximately 15 million ...

Since its approval in May 2015 through February 2017, the FDA has received 120 reports of serious cases of pancreatitis or death. The Food and Drug Administration (FDA) is warning patients and ...

The FDA issued a communication claiming Viberzi — a medicine used for patients with irritable bowel syndrome with diarrhea — could increase pancreatitis risk in patients without gallbladders. Here’s ...

Allergan announced the publication of the positive results of two Phase 3 trials of Viberzi (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Findings are published in ...